Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: Anticancer drug use at the end of life places potential extra burdens on patients and the healthcare system. Previous articles show variability in methods and outcomes; thus, their results are not directly comparable. This scoping review describes the methods and extent of anticancer drug use at end of life.
Methods: Systematic searches in Medline and Embase were conducted to identify articles reporting anticancer drug use at the end of life.
Results: We selected 341 eligible publications, identifying key study features including timing of research, disease status, treatment schedule, treatment type, and treatment characteristics. Among the subset of 69 articles of all cancer types published within the last 5 years, we examined the frequency of anticancer drug use across various end of life periods.
Conclusion: This comprehensive description of publications on anticancer drug use at end of life underscores the importance of methodological factors when designing studies and comparing outcomes.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10247343 | PMC |
| http://dx.doi.org/10.1007/s12094-023-03234-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Screening the Irish Marine Biorepository Identifies a New Bryostatin Analog as Potent Inhibitor of Activated B-Cells Diffuse Large B-Cell Lymphoma.
Chembiochem
September 2025
School of Biological and Chemical Sciences, Ryan Institute, University of Galway, University Road, Galway, H91 TK33, Ireland.
Activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL) is an aggressive cancer with poor response to standard chemotherapy. In search of new therapeutic leads, a library of 435 fractions prepared from the Irish marine biorepository was screened against 2 ABC-DLBCL cell lines (TMD8 and OCI-Ly10) and a non-cancerous control cell line (CB33). Active fractions are prioritized based on potency and selectivity.
View Article and Find Full Text PDFMitochondrial ClpX Inhibition Induces Ferroptosis and Blocks Pancreatic Cancer Cell Proliferation.
Chembiochem
September 2025
School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, 310024, P. R. China.
The ATPase caseinolytic protease X (ClpX), forming the ClpXP complex with caseinolytic protease P (ClpP), is essential for mitochondrial protein homeostasis. While ClpP targeting is a recognized anticancer strategy, the role of ClpX in cancer remains underexplored. In pancreatic ductal adenocarcinoma (PDAC), elevated CLPX expression correlates with poor prognosis, suggesting its oncogenic function.
View Article and Find Full Text PDFRecent advances in emerging applications and biological activities of tea polysaccharides and their conjugates from leaves and flowers: A review.
Int J Biol Macromol
September 2025
Department of Food Science and Nutrition, College of Biosystems Engineering and Food Science, Zhejiang University, Hangzhou, 310058, China. Electronic address:
Tea (Camellia sinensis) polysaccharides (TPS) and tea polysaccharide conjugates (TPC) are bioactive compounds found in tea leaves and flowers, attracting growing interest for their biological activities and emerging applications in food, pharmaceuticals, and cosmetics. Despite substantial progress in tea polyphenol research, studies focusing on TPS and TPC are still relatively underrepresented. This review fills a gap in the literature by summarizing the latest advancements in the extraction, characterization, and biological effects of TPS and TPC.
View Article and Find Full Text PDFGlucocorticoid Receptor-mediated Delivery of Paclitaxel and Anticancer Gene p53 for Oral Cancer Therapeutics.
Biomed Mater
September 2025
Department of Biological Sciences, Birla Institute of Technology & Science Pilani - Hyderabad Campus, Jawahar Nagar, Hyderabad, Hyderabad, Telangana, 500078, INDIA.
Metastasis in its micro and macro state contributes to the poor survival and prognosis rate in Oral Squamous Cell Carcinoma (OSCC) patients. Conventional anti-cancer treatments such as surgery, chemotherapy, and radiotherapy are known for their non-selective killing of rapidly dividing cells, both normal and cancer. To address the drawbacks arising from these modalities, we aimed to target the Glucocorticoid Receptors (GR) of OSCC to selectively co-deliver the Paclitaxel and p53 gene that induces the drug sensitivity and cytotoxicity, thereby inducing the mesenchymal-epithelial transition.
View Article and Find Full Text PDFPEGylated dendrimers for precision cancer therapy: Advances in tumor targeting, drug delivery, and clinical translation.
Biomater Adv
September 2025
Center for Global Health Research, Saveetha Medical College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India.
PEGylated dendrimers have emerged as highly adaptable nanocarriers for targeted cancer therapy, offering exceptional control over size, surface functionality, and drug loading. The covalent attachment of polyethylene glycol (PEG) chains to dendrimer surfaces improves biocompatibility, enhances circulation time, and minimizes immune clearance, facilitating passive tumor targeting through the enhanced permeability and retention (EPR) effect. These engineered nanosystems allow for precise encapsulation or conjugation of chemotherapeutic agents, nucleic acids, and imaging probes, with tunable release profiles.
View Article and Find Full Text PDF